JO2152B1 - Diabetes Mellitus - Google Patents
Diabetes MellitusInfo
- Publication number
- JO2152B1 JO2152B1 JO200180A JOP20010080A JO2152B1 JO 2152 B1 JO2152 B1 JO 2152B1 JO 200180 A JO200180 A JO 200180A JO P20010080 A JOP20010080 A JO P20010080A JO 2152 B1 JO2152 B1 JO 2152B1
- Authority
- JO
- Jordan
- Prior art keywords
- diabetes mellitus
- linalool
- handle
- control
- disease
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 abstract 4
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 abstract 2
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 abstract 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008103 glucose Substances 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 229930007744 linalool Natural products 0.000 abstract 2
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 229930003427 Vitamin E Natural products 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 239000003054 catalyst Substances 0.000 abstract 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract 1
- 108091005995 glycated hemoglobin Proteins 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 229940046009 vitamin E Drugs 0.000 abstract 1
- 235000019165 vitamin E Nutrition 0.000 abstract 1
- 239000011709 vitamin E Substances 0.000 abstract 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
This invention pertains to a method that can control, treat, and prevent Diabetes Mellitus. The method includes means of administering a potent product, including mainly the active ingredient Linalool, in any one of several forms, alone or with other additives and catalysts, such as vitamin E to enable the body to handle and control, then correct the complications of Diabetes Mellitus. A modest percentage of users suffering from this disease can be cured completely while the majority of others improve remarkably and experience lower blood glucose and reduce the glycated hemoglobin HbAlc readings to what are medically acceptable and healthy levels. Others, who are vulnerable to the disease due to hereditary factors, or other reasons, can help prevent it.; The method works in several ways, including activation of the pancreas and re-establishing the ability of body cells to utilize and handle better and well, the glucose in the blood, and regulate the level of natural insulin in the body. The method employs Linalool in any one of its forms that can be found naturally or synthetically
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JO200180A JO2152B1 (en) | 2001-05-23 | 2001-05-23 | Diabetes Mellitus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JO200180A JO2152B1 (en) | 2001-05-23 | 2001-05-23 | Diabetes Mellitus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO2152B1 true JO2152B1 (en) | 2002-08-07 |
Family
ID=48052106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JO200180A JO2152B1 (en) | 2001-05-23 | 2001-05-23 | Diabetes Mellitus |
Country Status (1)
| Country | Link |
|---|---|
| JO (1) | JO2152B1 (en) |
-
2001
- 2001-05-23 JO JO200180A patent/JO2152B1/en active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004052284A3 (en) | Treatment of diabetes | |
| NO20003051L (en) | Method of administration of AspB28 human insulin | |
| WO2005113590A3 (en) | Bmp10 propeptides and related methods | |
| WO2004050115A3 (en) | Combination treatment using exendin-4 and thiazolidinediones | |
| WO2006044531A3 (en) | Antisense modulation of ptp1b expression | |
| WO2007002572A3 (en) | Nattokinase for reducing whole blood viscosity | |
| WO2005065667A3 (en) | Compositions for treating or preventing obesity and insulin resistance disorders | |
| SG161234A1 (en) | A method and composition for nutritionally improving glucose control and insulin action | |
| PL1808168T3 (en) | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | |
| WO2005077072A3 (en) | Hybrid polypeptides with selectable properties | |
| NZ594044A (en) | Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics | |
| WO2005009398A3 (en) | Tetracyclic benzamide derivatives and methods of use thereof | |
| TNSN07191A1 (en) | Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy | |
| WO2002015920A3 (en) | Treatment of hyperproliferative diseases | |
| WO2004069181A3 (en) | Composition for the treatment of intraocular pressure | |
| WO2003039591A3 (en) | Allogenic vaccine that contains a costimulatory polypeptide-expressing tumor cell | |
| IL186356A0 (en) | Method of treating of preventing type-2 diabetes | |
| JO2152B1 (en) | Diabetes Mellitus | |
| WO2005117937A3 (en) | Alpha-1- acid glycoprotein for the treatment of diabetes | |
| WO2007056301A3 (en) | Antibody therapy for treatment of diseases associated with gluten intolerance | |
| WO2007042040A3 (en) | TREATMENT OF RETINOPATHIES USING GFRα3 AGONISTS | |
| WO2006004696A3 (en) | Compositions and methods for the prevention and control of insulin-induced hypoglycemia | |
| WO2010049590A3 (en) | A new pharmaceutical product | |
| WO2004098532A3 (en) | Methods of reducing an immune response | |
| WO2004054608A3 (en) | Lactoferrin in the reduction of pain |